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Clinical question: What is the most appropriate management of fungal keratitis?
Results: Traditionally, topical Natamycin is the most commonly used medication for filamen-
tous fungi while Amphotericin B is most commonly used for yeast. Voriconazole is rapidly 
becoming the drug of choice for all fungal keratitis because of its wide spectrum of coverage 
and increased penetration into the cornea.
Implementation: Repeated debridement of the ulcer is recommended for the penetration of 
topical medications. While small, peripheral ulcers may be treated in the community, larger or 
central ulcers, especially if associated with signs suggestive of anterior chamber penetration 
should be referred to a tertiary center. Prolonged therapy for approximately four weeks is usu-
ally necessary.
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Fungal keratitis 
Definition: Fungal keratitis (keratomycosis) is a fungal infection of the cornea. It 
primarily affects the corneal epithelium and stroma, although the endothelium and 
anterior chamber of the eye may get involved in more severe disease.
Incidence: Fungal keratitis is primarily seen in tropical climates and is rare in temperate 
areas. Its incidence is between 6%–20% of all microbial keratitis cases depending on 
the geographic location.1,2Traditionally, it is considered a disease of rural areas and is 
frequently caused by trauma with vegetative material. However, the major risk factor in 
developed countries is contact lens use at this time.3 Its incidence has been reported to 
be increasing due to widespread use of contact lenses, especially bandage contact lenses, 
and topical steroid usage.3,4 While tropical climates show a preponderance of filamentous 
fungi, temperate climates show higher percentages of yeast infections.1,5,6
Economics: Although no studies evaluating the economic implications of fungal 
keratitis are available, this is primarily a disease of young, working adults and is 
becoming more common. These facts, combined with the need for prolonged, inten-
sive treatment and relatively poor visual outcomes, suggest that the adverse economic 
implications are significant.
Level of evidence: Systematic reviews and randomized controlled trials (RCTs). 
Cohort and observational studies were also reviewed for additional data.
Search sources: PubMed, Cochrane Library.
Outcomes: The main outcomes are:
•	 Resolution of the infectious process as rapidly as possible





•	 Decrease in adverse outcomes such as the need for a 
therapeutic keratoplasty or loss of the eye.
Consumer summary: Fungal keratitis is an infection of the 
cornea by fungal organisms. It was traditionally thought to be 
caused by trauma with vegetative matter but contact lenses are 
now the most common etiology in developed countries. It is a 
difficult infection to treat and adverse outcomes such as the need 
for a corneal transplant or even eye removal are much more 
common compared to bacterial infections. Evidence suggests 
that this is because the current therapies are not very effective. 
Prolonged and aggressive therapy with antifungal medication 
and repeated debridement is necessary to treat this infection.7
Table 1 rCTs comparing the clinical response of different antifungal medications
RCT Intervention Number  
of patients
Outcome criteria Outcomes
Mohan 198815 Topical Silver sulphadiazine  
vs Miconazole 1%
40 Clinical response  
by healing of ulcer
Silver sulphadiazine superior  
to miconazole
rahman 199816 Topical chlorhexidine 0.2%  
vs natamycin 2.5%
70 response at day 5  
and healing by day 21
Chlorhexidine superior  
at both time points especially  
with severe ulcers
Prajna 200317 Topical econazole 2%  
vs Topical natamycin 5%
112 Clinical response  
by healing of ulcer
no difference
Kalavathy 200518 Topical itraconazole 1%  
vs Topical natamycin 5%
100 Clinical response  
by healing of ulcer
no difference overall but  
natamycin superior in Fusarium
Mahdy 201019 Topical Amphotericin  
B 0.05% + subconjunctival  
injection Fluconazole  
0.2% vs Topical  
Amphotericin 0.05%
48 Clinical response  
by healing of ulcer
Combination therapy  
superior to monotherapy
Prajna 201020 Topical voriconazole 1%  
vs Topical natamycin 5%
120 Time to  
re-epithelialization
no difference
Arora 201021 Topical voriconazole 1%  
vs Topical natamycin 5%
30 Clinical response  




RCTs	   7
Others	   2
There were three systematic reviews that evaluated 
the medical therapy of fungal keratitis. The Cochrane 
review8 in 2008 concluded that there was no evidence 
that the current available and investigational antifungal 
agents were effective. The review identified the need for 
large multicenter randomized trials. However, none of 
the studies they evaluated used either Amphotericin B or 
Voriconazole. The Hariprasad et al review9 evaluated over 
40 laboratory studies and clinical case reports of treatment 
with voriconazole and concluded that it may be used safely 
and effectively against a broad range of fungal pathogens. 
In 2000, the O’Day and Head review10 concluded that 
although there had been progress in the treatment and 
outcomes of fungal keratitis, it was painfully slow. This 
was partly due to the almost total absence of interest in the 
problem by the pharmaceutical industry.
Table 1 shows the various RCTs that compared various 
antifungal medications to each other in terms of clinical 
outcomes. However, there was no specific medication that 
was shown to be superior to the others. Only three studies 
evaluated the visual outcomes and adverse outcomes between 
medication and are shown in Table 2. In addition, there were 
two laboratory studies; one comparing antifungal medica-
tions for aspergillus in rabbits; and candida (isolates from 
41 countries) by disk diffusion shown in Table 3.
Conclusion
As the studies indicate, there is no one good broad spectrum 
anti-fungal medication that is effective in all cases of fungal 
keratitis. The initial therapy should be based on the organism 
suspected. While Natamycin is the only commercially 
available medication, it has a limited therapeutic spectrum. 
Voriconazole or Amphotericin B may be better first line 
drugs in unknown cases as they have broader efficacy. Other 
medications do not offer any improvement over these drugs 




Management strategies for fungal keratitis
Table 2 rCTs evaluating the visual outcomes or adverse outcomes between antifungal medications
RCT Intervention Number Outcome criteria Outcome
Mahdy 201019 Topical Amphotericin B  
0.05% + subconjunctival  
Fluconazole 0.2% vs Topical  
Amphotericin 0.05%
48 number of perforations  
and visual outcome
Both therapies equivalent  
in both criteria
Prajna 201020 Topical voriconazole 1%  
vs Topical natamycin 5%
120 visual acuity and number  
of perforations and corneal  
transplants
visual acuity slightly superior in 
voriconazole but not statistically 
significant. No difference in rate  
of complications
Arora 201021 Topical voriconazole 1%  
vs Topical natamycin 5%
30 visual acuity No significant difference
Table 3 Laboratory studies
Trial Intervention Number Outcome criteria Outcome
Panda 200312 Topical PHMB 0.02%  
vs povidone iodine  
1% vs natamycin 5%
24 Aspergillus  
rabbit infections
Healing time  
and perforations
natamycin most effective, 
PHMB less effective, 
povidone-iodine  
not effective
Pfaller 201022 Fluconazole (25 µg)  
vs voriconazole (1 µg)
256,882 Candida  
isolates
80% growth  
inhibition
voriconazole slightly  
superior but resistant  
organisms common to both
The practice
Potential pitfalls
Fungal organisms can penetrate through the corneal stroma 
without perforation of the cornea resulting in an infectious 
hypopyon or endothelial plaque. The problem is that the 
majority of antifungal medications have very poor penetration 
especially in the face of an intact epithelium. Unlike bacterial 
keratitis, the corneal epithelium overlying a stromal fungal 
infection can heal despite the presence of active infection 
once treatment is initiated and should not, by itself, be used 
as a guide to successful therapy.
Management
Fungal keratitis should be suspected in cases of keratitis that do 
not respond to antibacterial agents especially in cases of vegeta-
tive trauma or extended wear contact lens usage. These cases 
should be scraped and sent for KOH or Gomorimethenamine 
silver stains as well as culture on Saboraud agar.
Assessment
Feathery borders, ring infiltrate, endothelial plaque, fibrinoid 
aqueous, and satellite lesions should raise the suspicion of 
fungal keratitis (Figure 1). Endothelial plaques or an anterior 
chamber reaction usually indicate a more severe infection 
with penetration of fungal elements into the anterior cham-
ber (Figure 2). Response to therapy is usually indicated 
by blunting of the feathery edges, re-epithelialization, or 
reduction in the anterior chamber reaction.
Treatment
The only commercially available antifungal drug in the 
United States is Natamycin (also called Pimaricin) available 
as a 5% suspension. In other parts of the world where ker-
atomycosis is seen much more frequently such as India, 
additional antifungal agents such as Fluconazole and 
Miconazole are available. However, various other drugs can 
be compounded into eye drops (by compounding pharma-
cies) and are effective. The most commonly used drugs are 
Voriconazole (1%),7,11 Amphotericin B (0.15%), Fluconazole, 
and Miconazole. Antiseptics such as Chlorhexidine 0.2% and 
Povidone iodine (5%) have also been advocated as cheap and 
easily available alternatives but are not as effective.12 Sys-
temic antifungal medications have been advocated as adjunc-
tive therapy in severe cases, especially ulcers with anterior 
chamber reaction but there have been no controlled studies 
showing a clear benefit of adding systemic antifungals.13,14
Therapy should be aggressive and most authors advocate 
dual therapy to avoid the risk of resistance. Typically, the 
topical antifungals are given every hour initially. The dura-
tion of treatment is from 3–4 weeks on average. If efficacy is 





Figure 1 Typical fungal ulcer with feathery borders.
Figure 2 Endothelial plaque, ring infiltrate, and hypopyon indicating a more advanced 
infection.
should be given to changing the medication to another class 
or asking the laboratory to run sensitivities on the cultured 
fungus.
If the infection continues to worsen or there is worsen-
ing anterior chamber reaction, surgical management may 
be indicated. This includes therapeutic keratoplasty and, in 
severe cases, enucleation may be necessary.
indications for specialist referral
Small, superficial, peripheral ulcers can be managed in the 
community with a combination of frequent antifungal agents 
and epithelial debridement every three days. Large, deep, 
or central ulcers with an endothelial plaque, a hypopyon or 
fibrinoid aqueous should preferably be referred to a cornea 
specialist within a day. Paracentral ulcers may be managed 
in the community if smaller and without evidence of anterior 
chamber penetration. However, if no response is noted within 
a week, the physician should consider referring the patient 
to a specialist.
Further reading
•  Krachmer JH, Mannis MJ, Holland EJ. Cornea 3rd edition, volume 1. 
Fundamentals, diagnosis and management. Elsevier Mosby: Philadelphia, 
PA; 2010.
•  Kalkanci A, Ozdek S. Ocular fungal infections. Curr Eye Res. 2010;15. 
Epub. 
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